Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of warfarin therapy after a first venous thromboembolic event is however a matter of some controversy and many questions remain unanswered. After reviewing and analysing the available evidence, we discuss some common scenarios in everyday clinical practice where treatment decisions are difficult. © 2008 Fonseca and D'Cruz; licensee BioMed Central Ltd.
Fonseca, A. G., & D’Cruz, D. P. (2008). Controversies in the antiphospholipid syndrome: Can we ever stop warfarin? Journal of Autoimmune Diseases. https://doi.org/10.1186/1740-2557-5-6